Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

224results about How to "Reduced dos" patented technology

Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant

Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.
Owner:PURDUE PHARMA LP

Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent

InactiveUS20030124185A1Analgesic and euphoric effect be reduce and eliminateCompromise integrityPowder deliveryPill deliveryOpioid antagonistDrug
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage form after tampering.
Owner:PURDUE PHARMA LP

Tapered hollow metallic microneedle array assembly and method of making and using the same

The present invention includes device, system, method of using and making a microneedle array including the steps of forming one or more pins on a substrate, depositing one or more layers on the one or more pins and the substrate, exposing a portion of the one or more pins, and separating the one or more pins from the one or more layers to form the hollow microneedle array.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Catheter device with a position sensor system for treating a vessel blockage using image monitoring

The invention relates to a catheter device, with a position sensor system, for treatment of a partial or complete vessel blockage under image monitoring, with the catheter device featuring a treatment catheter of a vessel blockage, especially by removal or destruction of plaque and / or expansion of the vessel,, which is embodied as an integrated unit, especially as a combination catheter, with an OCT catheter and an IVUS catheter for image monitoring and with the position sensor system.
Owner:SIEMENS HEALTHCARE GMBH

Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists

InactiveUSRE36547E1Enhance analgesic potencyDecrease dependence liabilityCompound screeningBiocideEndogenous OpiatesNervous system
This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administration of said bimodally-acting opioid agonists comprising the co-administration of a bimodally-acting opioid agonist which activates both inhibitory and excitatory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an opioid receptor antagonist which selectively inactivates excitatory opioid receptor-mediated side effects. This invention also relates to a method of using excitatory opioid receptor antagonists alone to block the undesirable excitatory side effects of endogenous bimodally-acting opioid agonists which may be markedly elevated during chronic pain. This invention further relates to a method of long-term treatment of previously detoxified opiate, cocaine and alcohol addicts utilizing said excitatory opioid receptor antagonists, either alone or in combination with low-dose methadone, to prevent protracted physical dependence, and to compositions comprising an excitatory opioid receptor antagonist of the invention and a bimodally-acting opioid agonist.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV

Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

ActiveUS20120004251A1Well side effect profileGrowth inhibitionBiocideNervous disorderPhenobarbitalDrug
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
Owner:GW PHARMA LTD +1

Stable pharmaceutical compositions

A pharmaceutical dosage form, comprising an outer capsule containing at least one capsule, tablet, and / or particles comprising different drug substances.
Owner:DR REDDYS LAB LTD

Treatment of cancer with active vitamin D compounds in combination with radiotherapeutic agents and treatments

InactiveUS20060177374A1Treating and ameliorating cancerReduced hypercalcemicBiocideOrganic active ingredientsCompound (substance)Treated animal
The present invention relates to a method for treating cancer in an animal by administering to the animal an active vitamin D compound or a mimic thereof in combination with a radiotherapeutic agent or treatment.
Owner:NOVACEA INC

Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors

InactiveUS7211562B2Avoid or reduce their respective toxicity to patientsGrowth inhibitionHeavy metal active ingredientsPeptide/protein ingredientsBinding siteRadicicol
The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.
Owner:SLOAN KETTERING INST FOR CANCER RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products